department of pharmacology



David C. U'Prichard, Ph.D. 

Druid Consulting LLC

Dr. David C. U'Prichard currently serves as a President of Druid Consulting LLC, consulting to the pharmaceutical and biotechnology industries from his base in Philadelphia, US, and as a Venture Partner at Red Abbey Venture Partners (Baltimore) .He has served as a Venture Partner for Apax Partners Ltd. (London) and Care Capital LLC (Princeton) and was the CEO and a member of the Board of Directors of 3-Dimensional Pharmaceuticals, Inc., Yardley PA. He also took 3DP public and secured large collaborations with Bristol-Myers Squibb and Johnson & Johnson.

In the late 1990¡¯s Dr. U'Prichard served as Chairman of Research and Development at SmithKline Beecham, overseeing the entry of approximately ten compounds into global development, the international registration of the diabetes drug Avandia and the entry of four compounds into Phase III trials and six compounds into early clinical trials. Prior to joining SmithKline Beecham, he worked for ICI/Zeneca, as Executive Vice President and International Research Director from 1994 to 1997.

Dr. U'Prichard received his Ph.D. in Pharmacology from the University of Kansas, and his B.S. in Pharmacology with first-class honors from the University of Glasgow, Scotland. He has held academic appointments at Northwestern University, Johns Hopkins University and the University of Pennsylvania and is an Honorary Professor at the University of Glasgow. In addition to various other achievements, he is also an author of more than 100 primary and review publications, was a founding co-editor of Molecular Neurobiology and co-editor of Epinephrine in the Central Nervous System and has served as a member of various editorial boards.